ALK and neoplasm: Our results provide strong evidence that ASP3026 could represent a novel and successful therapeutic strategy to eradicate this aggressive lymphoma and that patients with NPM-ALK+ ALCL, including those with crizotinib resistance, should be enrolled in the current clinical trials testing the effects of ASP3026 in ALK+ neoplasms.